史賽克 (SYK) 2020 Q4 法說會逐字稿

Welcome to the Fourth Quarter 2020 Stryker Earnings Call. My name is David, and I will be your operator for today's call. (Operator Instructions) This conference call is being recorded for replay purposes.

Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC.

I will now turn the call over to Mr. Kevin Lobo, Chairman and Chief Executive Officer. You may proceed, sir.

Welcome to Stryker's fourth quarter earnings call. Joining me today are Glenn Boehnlein, Stryker's CFO; and Preston Wells, Vice President of Investor Relations. For today's call, I will provide opening comments, followed by Preston with an update on the current environment and our most recent acquisitions. Glenn will then provide additional details regarding our quarterly results before opening the call to Q&A.

I would like to start my comments by expressing my appreciation for the perseverance shown by our employees as they work through the many challenges that we faced during 2020. Throughout the year, we maintained high employee engagement while continuing to support surgeons and caregivers around the world.

Our fourth quarter organic sales declined roughly 1%, reflecting the impact of a resurgence of COVID-19 infections, offset by a continuation of emergent procedures and strong performance by our large capital products. We are also excited about closing the Wright Medical deal during the quarter and the category leadership that we gained in the fastest-growing segment within the orthopedics market. Preston will provide some additional updates on the integration shortly.

Throughout the quarter, we maintained the financial discipline instituted at the beginning of the pandemic, which, combined with a favorable tax rate, led to an adjusted earnings per share of $2.81 in the quarter, up approximately 13% versus 2019. And we delivered impressive cash flow from operations, which exceeded $3 billion for the full year.

In addition to closing the Wright Medical acquisition, we also made progress in many areas that will provide future growth opportunities. We have established a structure focused on digital, robotics and enabling technology, where we see a significant opportunity to create a company-wide unified digital ecosystem, including Mako. We maintained our commitment to drive innovation across our various business units, including Neurovascular, where we gained new product approvals across Aspiration, stent retrievers and flow diverting stents, and in our MedSurg segment where we continue product introductions with a focus on safety and prevention.

Finally, we successfully launched our ASC sales model, which leverages the Stryker portfolio to provide end-to-end solutions to meet the growing demand and shift to the outpatient setting. Our continued support for our customers and our commitment to innovation will position us well for growth as the pandemic eventually subsides.

Turning to 2021. Our people and culture of execution remains strong, which will allow us to deliver on our commitment to make health care better and to resume our customary strong organic sales growth and leveraged earnings.

With that, I'll now turn the call over to Preston.

Thanks, Kevin. My comments today will provide an update on the current environment, trends related to the latest COVID-19 impacts and updates on our most recent acquisitions of Wright Medical and Orthosensor. During the fourth quarter, elective procedures were negatively pressured in most regions globally as localized infection and hospitalization rates surged through the month of December. As a result, growth was uneven and correlated to the state of the pandemic in each region. The areas impacted the most include the U.S. and many of the countries in Western Europe, most notably, the United Kingdom, driven by a countrywide lockdown.

Even with the procedural variability, we saw growth in emerging markets, including China, which grew double digits over prior year quarter. Looking forward, hospitals are better equipped to handle this resurgence, and they are working to bring back the procedures that have been delayed. But we expect that the variability of elective procedures will continue during the first quarter until infection rates begin to decline and the distribution of the vaccines become more prevalent. This slowdown in elective procedures had a negative impact on our more deferrable businesses, which make up approximately 40% to 50% of our total sales.

However, the slowdown this quarter was not as impactful as the decline in the second quarter as hospitals were better equipped to manage COVID patients while maintaining some level of elective surgeries. Despite the overall slowdown, we experienced continued growth in our Neurovascular, Medical, Mako and Upper Extremities businesses. Specifically, demand for Medical's large capital products continued in the fourth quarter, driven by the focus on expanding bed capacity, the need for our emergency care products, like power cot and the LUCAS device, and the availability of some remaining CARES Act funding in the U.S. In addition, the early trends in the launch of our new ProCuity bed are positive and expect it to continue into 2021.

During the year, our Mako installed base grew by 33% and exceeded another milestone with over 100 robots sold and installed in the fourth quarter. This growth continues to highlight the demand for our differentiated Mako robotic technology as well as our ongoing success selling and installing robots in major teaching institutions, ASCs and competitive accounts.

We are also excited about our recent approvals for Mako TKA in China, Russia and Brazil, which all provide opportunities for growth as these markets continue to embrace robotic, digital and enabling technologies.

Turning to U.S. knee procedures. In the fourth quarter, approximately 44% of our total knees were Mako Knee procedures, a trend that continues to increase. The shift towards cementless knees also continued, and in the fourth quarter, cementless knees made up 42% of our U.S. knee procedures.

During the pandemic, feedback from surgeons has pointed to limited trialing of competitive products in businesses like joint replacement as surgeons work to perform procedures restricted by cancellations and deferrals. However, as the pandemic subsides and we return to a more normal environment, we expect to continue to outpace the market driven by our Mako installations throughout the year and our strong order book heading into 2021.

We are also enthusiastic about the Wright Medical acquisition and the category leadership we gained in both upper extremities and foot and ankle through Wright's diverse portfolio of implants, biologics and enabling technologies. The combination of Stryker and Wright will continue to drive innovation that enhances our customers' ability to address patient needs across the more than $3 billion extremities market.

The integration has been progressing well over the last few months. The long period from sign to close was used to ensure that the appropriate integration plans were in place, leveraging our years of deal experience. To date, the teams have been focused on moving quickly to align the new combined organization. Considerable progress has been made, including the creation of specialized business units and sales forces for trauma, upper extremities and foot and ankle, which is a key part of our overall decentralized strategy that allows us to remain close to the customer.

The U.S. sales leadership organizational structure for these 3 specialized business units has been announced, and the rollout and full alignment of territories will be finalized during the first quarter, as planned. Outside the U.S., the leadership team is working to align the sales forces throughout the year. Our teams are executing the sales integration while continuing to drive day-to-day business. And during the quarter, there was minimal disruption caused by the closing and integration activities.

Finally, I want to restate our ongoing commitment to M&A, which was most recently demonstrated by our acquisition of Orthosensor, a leader in the digital evolution of musculoskeletal care and sensor technology for joint replacement. Smart devices and implants will play an important role in the future of orthopedics, and the addition of Orthosensor will allow us to continue to innovate and advance smart sensor technology, including interoperative sensors, wearables and ultimately, smart implants.

As it relates to 2021 guidance, Glenn will provide an update on our full year guidance for sales, operating margin and EPS. Updates to this annual guidance will be made each quarter as necessary throughout the year.

With that, I'll now turn the call over to Glenn.

Thanks, Preston. Today, I will focus my comments on our fourth quarter financial results and the related drivers. Our detailed financial results have been provided in today's press release.

Our organic sales decline was 1.1% in the quarter. As a reminder, this quarter included the same number of selling days as Q4 2019. Pricing in the quarter was unfavorable 0.8% from the prior year, while foreign currency had a favorable 1.2% impact on sales.

Early in the quarter, there was continued momentum from Q3. However, during November, the impact of the resurgence of COVID-19 and the related cancellations of procedures, primarily in the U.S. and Europe, significantly impacted our sales momentum. However, we did see demand for certain capital products continue as we had strong results in our Mako, medical beds and emergency care products.

For the quarter, U.S. organic sales declined 1.5%, reflecting the slowdown in elective procedures as a result of the pandemic, somewhat offset by strong demand for Mako, Medical products and Neurovascular products. International organic sales were flat, impacted by the resurgence of the COVID-19 pandemic, primarily in Europe, which was mostly offset by growth in Canada, China and Brazil. Organic sales decline for the year was 4.8%, with a U.S. decline of 5.8% and an international decline of 2.1%.

2020 had 1 additional selling day compared to 2019. And for the year, price had an unfavorable 0.7% impact on sales. Our adjusted quarterly EPS of $2.81 increased 12.9% from the prior year, reflecting strong financial discipline, good operating expense control and a favorable operational tax rate. Our fourth quarter EPS was positively impacted by $0.03 from foreign currency. Our full year EPS was $7.43, which is a decline of 10%, reflecting the impact of lower sales, especially in Q2, as well as the impact of idling certain manufacturing facilities during the year, offset by strong expense discipline throughout the year.

Now I will provide some highlights around our segment performance. Orthopaedics had constant currency sales growth of 2.8% and an organic sales decline of 5.8%, including an organic decline of 5.7% in the U.S. This reflects a slowdown in elective procedures related to COVID-19 and a very strong prior year comparable as Q4 2019 U.S. organic growth was 7.2%. Other ortho grew 12.3% in the U.S., primarily reflecting strong demand for our Mako Robotics platform, partially offset by declines in bone cement. The Trauma and Extremities business also delivered positive growth, led by our core trauma and shoulder products.

Internationally, Orthopaedics declined 6% organically which also reflects the COVID-19-related procedural slowdown, especially in Europe. This was somewhat offset by stronger performances in Australia and Canada.

During the quarter, the Wright Medical acquisition was successfully closed. For the quarter, Wright delivered flat growth on a comparable basis. This included positive performances in U.S. shoulder, double-digit growth in U.S. ankle as well as strong international growth led by Australia. On a comparable basis for the full year, Wright had a 10.3% decline, mainly driven by the COVID-19-related slowdown in the second quarter.

In the quarter, MedSurg had constant currency growth of 1.5% and organic growth of 1.3%, which included 2.2% growth in the U.S. Instruments had U.S. organic sales growth of 4.5%. In the quarter, sales growth was driven by gains in its power tool, waste management and smoke evacuation products and its service business.

Endoscopy had a U.S. organic sales decline of 7%, primarily impacted by the slowdown in the capital businesses, offset by gains in the Sports Medicine business, which grew over 9% in the quarter. The Medical division had U.S. organic growth of 9.7%, reflecting solid performances in patient care, emergency care and its Sage businesses. Internationally, MedSurg had an organic sales decline of 2.4%, reflecting a general slowdown in Instruments and Endoscopy businesses and strong comparables across most geographies.

Neurotechnology and Spine had constant currency and organic growth of 2.1%. This growth reflects many strong performances within our Neurotech product line, including neuro-powered drills, Sonopet and Neurovascular, offset by the impact of procedural deferrals, especially in the U.S. Our Europe -- our U.S. Neurotech business posted an organic decline of 1.2% as procedural deferrals impacted sales in the quarter. Internationally, Neurotechnology and Spine had organic growth of 13.5%. This performance was driven by strong demand in Australia, Japan and China.

Now I will focus on operating highlights in the fourth quarter. Our adjusted gross margin of 65.1% was unfavorable approximately 120 basis points from the prior year quarter. Compared to the prior year quarter, gross margin dilution was impacted by price, business mix and unabsorbed fixed costs as production was brought in line with reduced demand during the quarter. This was primarily offset by acquisitions and foreign exchange.

Adjusted R&D spending was 5.5% of sales. Our adjusted SG&A was 30.3% of sales, which was favorable to the prior year quarter by 200 basis points. This reflects the continued focus on disciplined operating expense controls, which have been in place since the second quarter. These cover most of our discretionary spending, including curtailments in hiring, travel, meetings and consultants.

In summary, for the quarter, our adjusted operating margin was 29.2% of sales, which is a 90 basis point improvement over the prior year quarter and reflects the impact of the spending discipline previously discussed. Related to other income and expense as compared to the prior year quarter, we saw a decline in investment income earned on deposits and interest expense increases related to increases in our debt outstanding related to the funding of the Wright Medical acquisition. Our fourth quarter had an adjusted effective tax rate of 8%. Our full year effective tax rate was 12.6%.

These rates reflect onetime operational fluctuations that arose due to the pandemic, with a mix of foreign losses related to lower foreign manufacturing activity combined with reduced U.S.-sourced income that resulted from the sharp drop in sales at the end of the year. For 2021, we do not anticipate these circumstances arising as we expect to return to normalized operations during the year. And we expect our full year effective tax rate to be in the range of 15.5% to 16.5%.

Focusing on the balance sheet. We ended the year with $3 billion of cash and marketable securities and total debt of $14 billion. During the quarter, we executed the Wright Medical acquisition, which resulted in the disbursement of $5.6 billion, inclusive of the retirement of Wright's convertible debt.

Turning to cash flow. Our year-to-date cash from operations was approximately $3.3 billion. This historically strong performance resulted from the disciplined working capital management, somewhat offset by lower earnings.

Turning to cash flow for 2021. We will not be repurchasing any shares, and we anticipate that capital expenditures will be approximately $650 million. Anticipating a more normalized year in 2021 and a ramping of investment in our businesses, we expect the free cash flow conversion rate as a percent of adjusted net earnings excluding the onetime impacts from the Wright Medical integration of 70% to 80%.

And now I will provide 2021 guidance on a stand-alone legacy basis and further guidance, including Wright Medical. We are providing our guidance in comparison to 2019 as it is a more normal baseline given the variability throughout 2020. As Preston indicated, we will be providing annual guidance on our organic sales growth and earnings, and we'll update this throughout the year as part of our regular earnings calls.

As we assess the current operating environment, we believe that the recovery ramp of elective procedures will continue to be variable based on region and geography and will continue into the second quarter of 2021. Given this variability, we expect organic sales growth to be in the range of 8% to 10% for the full year 2021 when compared to 2019. As a reference, our organic sales growth excludes Wright Medical. There are the same number of selling days in 2021 compared to 2019 and 1 less when comparing to 2020.

Consistent with the pricing environment experienced in both 2019 and 2020, we would expect continued unfavorable price reductions of approximately 1%. Additionally, as we are comparing growth to 2019, our 2021 organic sales growth guidance includes 2 years of price reductions. If foreign exchange rates hold near current levels, we anticipate sales in EPS will be modestly favorably impacted as compared to 2020 and 2019.

For the full year 2021, we did not expect to deliver operating margin expansion as a result of the op margin dilution of the Wright Medical acquisition. However, excluding the dilutive impact from Wright, we do anticipate expansion of 30 to 50 basis points of operating margin in 2021 for our legacy Stryker business compared to 2019. This includes anticipated increases in hiring, discretionary expenses and other costs that support future growth and business expansion as our businesses continue to ramp back to more normalized levels.

Finally, for 2021, we expect adjusted net earnings per diluted share to be in the range of $8.80 to $9.20 for the full year. This includes the previously announced $0.10 dilution driven by the addition of the Wright Medical business for the full year. While Wright Medical is dilutive in 2021, we expect it to be accretive starting in 2022.

As it relates to other aspects of Wright Medical, we expect comparable growth for Trauma and Extremities to be in the low to mid-single digits in 2021 when compared to 2019. This includes the integration of Stryker's legacy extremity business with Wright Medical, which will all be part of our Trauma and Extremities division. This growth is impacted by the recovery from COVID-19, partially offset by dis-synergies from the integration activities in 2021. We also reiterate our previous guidance on cost-saving synergies from the deal of approximately $100 million to $125 million over the next 3 years.

And now I will open up the call for Q&A.

(Operator Instructions) Your first question comes from the line of Vijay Kumar with Evercore.

Congrats on the Q here. And I guess maybe a high-level start off on the guidance question here, 8% to 9% organic for the base business. What are we assuming for Wright Medical here for growth for fiscal '21?

Yes. Vijay, sorry, I was on mute. Yes, our organic guidance is 8% to 10%. And the guidance that we provided related to Wright Medical, you have to understand that it's being integrated into our Trauma/Extremities businesses. So we will be combining in our legacy Extremities business with Wright Medical and running that combined group as part of our Trauma/Extremities division.

So when you mix all that together and you really look at what will Trauma and Extremities growth be in 2021 as compared to 2019, we do think it will be low to mid-single digits. But keep in mind that also takes into account sales dis-synergies for Wright Medical that we fully expect will happen in 2021.

Understood. And Glenn, maybe if I could add, just one quick one on the margins for cash. I mean Q4 was really impressive, the margin on the OpEx side. And if I look at the guidance here, perhaps it seems a little conservative. And I look at the EPS guidance range, it's coming in a little bit wider versus the typical Stryker in the guidance range, if you will. What would cause -- I mean that's almost 100 basis point swing between the low end and the high end. Perhaps talk about what goes in at the low end and the high end.

Yes. It's -- Vijay, I would tell you that based on what happened this year and the variability that we saw in our operations, we fully expect to continue to experience some variability on into Q2. And so our guidance range really reflects how that ramp comes back.

On the low end, it could be all the way through Q2. On the better end, we start to see much more improvement towards the beginning of Q2. And it really is going to be variable depending on that. I mean we have passed our legacy Stryker business on the op margin front with 30 to 50 basis points improvement. But keep in mind, as you look at Q4 or if you even go back and look at Q3, it really reflected a pretty Draconian expense control in terms of hiring, travel, meetings, consultants, you name it, discretionary expenses, and we put the lid on that.

So that's not sustainable, especially as you think about our aspirations to grow at the high end of med device. And So we will start seeing that spending pick up as we continue to supplement and hire our sales forces, as we meet with customers, as we add to our prototypes and loaner pools, all those things will start to add to our expenses. And so that's really what's underlying the guidance.

Your next question comes from the line of Bob Hopkins with Bank of America.

So just 2 quick things. Glenn, just to clarify that guidance on the revenue side. I appreciate that you're guiding to organic growth. But it sounds like Wright Medical was flat in the quarter, which is actually pretty impressive. So I come out to a little bit over $17 billion for the year, just based on kind of your guidance of 8% to 10% organic. And then I'm just tacking on $900 million to $1 billion for Wright Medical and getting to a little over $17 billion. So I was wondering if you thought that was in the ballpark.

Yes. Bob, again, I just can't reiterate the variability that we're seeing. And so maybe that's sort of adding up the obvious set of numbers, if you will. I think we picked the range 8% to 10% because we do feel like there is going to be some variability that we can't exactly forecast at this point in time and where we're sitting in Q1 and what we're seeing.

As far as Wright Medical goes, we were pretty pleased with where their Q4 performance came out, but they're also subject to a lot of the same variability, which is why we're looking that once we integrate it with Trauma and Extremities, we will have some sales dis-synergies that just naturally occur. We felt that with K2 and Spine, and we will fill that with Wright Medical. So taking into account that variability, you're really looking at 8% to 10% for the -- for Stryker legacy and low to mid-single digits as we look at the combined Wright and Trauma and Extremities.

Okay. Fair enough. And then, Kevin, just quickly for you. Just curious to get your kind of macro perspective on what you're seeing out there as far as the current state of the business right now. Hospitals' willingness to buy capital, kind of where we are in terms of procedure growth? Just would love an update given the environment is so volatile on what you're seeing right now. I think that would be helpful.

Yes. Thanks, Bob. I would say, certainly, at the end of the year, really did we got that second wave spiking. And certainly, you saw that in the discretionary procedures, a pretty big slowdown after a pretty good month of October. And it really started to tail off November, December.

On the large capital front, we're actually very excited. So what we experienced through Q2, Q3 and Q4 from an order book standpoint is continuing to be very strong. So that is really good news. It's good news for Mako. It's good news for Medical.

On the small capital side, we've always said that, that tends to lag a little bit, the recovery in discretionary procedures. And you certainly saw that within certainly the Endoscopy division and the Instruments division, where I would say that those orders are maybe going to take a little longer to really come back in the same way. But overall, I mean, we have enough confidence now with the hospitals being ready to do these procedures as soon as the pandemic starts to subside, as soon as vaccines start to become more prevalent that they'll turn it on pretty quickly, and they'll be pretty agile. And that's why we feel pretty confident of being able to give, I think, a healthy guide, certainly going back off of '19, 8% to 10% organic.

So we -- so it will spike throughout the year, starting with, obviously, a slower Q1. And the good news is we have the whole year. So even if the discretionary procedures drag a little bit, we saw in Q3 a pretty big spike once things started getting healthy. So over the course of the year, we're hoping that and believe that the guidance we'll be able to sustain. Even if it's maybe a little softer in Q2 and a little stronger maybe in Q3.

Your next question comes from the line of David Lewis with Morgan Stanley.

Just 2 quick ones for me. Kevin, I was sort of comparing the revenue guide, the earnings guide. And your earnings guide is kind of interesting to me in that it's basically 12% earnings growth, which you guys were doing kind of the last couple of years minus Wright Medical. But the revenue goes a little higher, right? The 8% to 10% over '19 is a little better than the earnings growth guidance. So it's above your structural growth rate, but I think some would argue probably should be, just given in light of the recovery. So should we interpret that 8% to 10% number, Kevin, relative to the structural growth rate? And what are some of the key factors underpinning that? Or how do you think about the structural growth rate of Stryker here as we come out of COVID-19? And then I have a quick follow-up.

Sure. Sure, David. I mean without getting into every single division, what I would just give you as a macro comment is we feel that we have the right offense to continue to win in the market and to continue the strong growth. You saw for 7 straight years, we accelerated our organic growth, and 2019 culminated with over 8% organic growth. And I think that muscle that we developed, the structure that we have with our business units, the new product pipeline that we have, has positioned us to be an above-market grower. And we expect -- fully expect that, that will continue into 2021.

There are obviously differences by divisions, but we feel like we're in a very healthy position overall. And that's what gives us confidence in the guide.

Clearly, Wright Medical is a big acquisition. There are dis-synergies that we've assumed there. It was highly dilutive to the normal operation of our business. We'll see how that unfolds over the course of the year. The early signs of the integration are very positive, but we have put in some prudence there just based on what we've experienced with our K2M acquisition and what, frankly, all other implant companies have experienced with their integration.

Okay. Very helpful. And then just lastly just on ortho competitiveness. Kevin, I know the environment is very, very invisible. All we have is sort of one competitor results to go after here. Any reason to believe your momentum has changed at all? I mean your robotic system placements are very strong. And you kind of went from 30% knees and cementless robotic to 40% pretty darn quickly during COVID. But any reason to believe that your relative positioning or relative share momentum versus other peers in '21 is going to look a lot different?

Yes. No, we remain very bullish about our general replacement business as well as Mako. You saw just the increase in Mako is pretty remarkable to have almost 1 out of 2 knees being done on Mako, and it's not been that many years since we launched the system. So unlike Navigation in the past, which obviously never had this type of an uptake, we continue to have strong, not only installations of robots but utilization. And even Hips, we're seeing that continue to increase as well. And the new Hips software was installed in about 400 accounts in Q4. So we had the approval, obviously, earlier in the year. But because of the pandemic, it's taken us time to actually be able to go in and do the upgrades, but that will pick up steam again into 2021.

So again, looking at 1 quarter, whether it's a positive or negative in a pandemic world, is not something I'm too concerned about. It's just based on where your regional strength is. If you happen to be in a state or locality that is doing procedures, then you got benefit, and if you didn't, you got hurt. So it's a little bit random during the pandemic, but structurally, I think we're in great shape with that business.

Your next question comes from the line of Larry Biegelsen with Wells Fargo.

This is Shagun in for Larry. I wanted to touch on the acquisition of Orthosensor. Kevin, the acquisition really marks your entry into the sensor technology, remote patient monitoring and smart implant plan space in a much more meaningful way. And I was wondering if you could comment on the timing here. Why now, given that you've had a relationship with them for several years for soft tissue balancing?

And then how are you thinking about time lines for integration and launch with Mako? And then also the launch of smart implants, any timing you could share? And also, if I could squeeze in one more, how are you thinking about the application of sensor technology beyond knees into shoulders and hips. Anything on timing would be great.

Yes. Shagun, this is Preston. Just in terms of the timing of the deal itself, I mean, again, we are constantly looking at different opportunities. And it was just the right time with the team to make this acquisition in terms of what we thought we were able to do with it. So I think just the timing of it just happened to work out the way that it did. And we typically do look at our targets for a long period of time.

In terms of other time lines about when we're going to be bringing some of the different things to market, we're not -- at this point, we're not ready to disclose those time lines. Just know that the teams are getting to work to develop a pretty robust time -- excuse me, robust pipeline around that sensor technology. And as we have more information, we'll certainly be bringing that to you guys.

Your next question comes from the line of Robbie Marcus with JPMorgan.

Kevin, I was hoping you could comment on as you're thinking about later this year and into next year, there were a lot of patients that didn't end up getting procedures in 2020 and probably the first half of 2021. How should we think about the potential for a bolus of patients? I realize there's limitations to what the system can do, but there's still a lot of patients that need to be treated. So how are you thinking about that as an organization?

Robbie, it's Preston. I'll take that one. In terms of that patient backlog, certainly, we saw some of that being worked down in the third quarter as we saw the recovery starting to happen. And certainly, as then we saw more deferrals happening in the fourth quarter, you saw more people being added back to that backlog.

And as Kevin and Glenn both articulated, as we see the recovery happening in 2021, we would expect to see some of that recovery include the backlog of patients that have been deferring now for -- anywhere from 3 to 6 months or so. And so we would expect to see some of that flowing back into the numbers through 2021.

I think the one caveat I would give you is you won't necessarily see a dramatic spike in those numbers just given certain aspects around capacity and things like that. So you'll still see surgeons and hospitals working to fit additional surgeries in and things -- the same things that we saw in the third quarter. But you certainly won't see a significant dramatic spike at any one point in time as a result of that backlog.

Great. And maybe just one more question on Neurovascular. I remember in 2019, back in the old days before COVID, you were hoping to at least accelerate that business in 2020. You had some new product launches. I was hoping you could just give us the update on where you're going to have new product launches in 2021 and how you're thinking about that business.

Yes. Thanks, Robbie. First of all, Neurovascular had a really terrific year. They had double-digit growth in the fourth quarter. They were obviously, just like everybody else, affected in the second quarter and into the third quarter. But double-digit growth in the fourth quarter, extremely exciting portfolio of products, new product introductions that -- obviously, with Aspiration, we have the Vecta 074 catheter out. We have the pump. They're doing very well. They have this flow diverting stent, the second-generation flow diverting stent approved in the United States that surpass Evolve. We have the first-generation flow diverting stent approved in China. Our Atlas stent, which is used to -- in hemorrhagic segment, adjunctive stent is doing extremely well in China. So we really have a great portfolio. And we have the NXT, the next-generation stent retriever as well recently launched.

So a lot of new launches. This management team is truly outstanding. They've been in place since, frankly, we acquired the business. They have a very healthy pipeline of other products coming as well. So I'm very, very bullish on the Neurovascular business. They ended the year with great momentum, and I expect they'll continue to be a very strong performer in the years to come.

Your next question comes from the line of Pito Chickering with Deutsche Bank.

One quick guidance question for you. And I understand you're not providing quarterly guidance at this time. But normally, you get about 23% of your annual EPS in the first quarter. And because you're still seeing pressures in deferrable procedures in January, is there any chance to give some color that they can give some cadence of their first quarter earnings versus your normal run rate?

Yes. Pito, I would just tell you, and this is -- we're not in the normal run rate period, right? I mean I think we're still coming out of some pretty variable trends that we saw in the fourth quarter and continuing certainly into the first quarter. A lot of it's going to depend on the localized hospitalization and infection rates and really how those decline over time and how the vaccine is out there and more prevalent. So I think that's what I would continue to look at as we think about what that recovery trend is going to be. At this point, it would be too hard really to give you too much guide on how that's going to exactly happen. And that's why you see the wider guidance that we've provided.

Okay. Fair enough. And also for a follow-up, as more procedures are moving into the ASCs due to COVID to free up OR space and its capacity in the systems, have you seen hospitals change their purchasing habits to buy the cheaper implants or push back on pricing or to adapt to the lower reimbursements in the ASCs?

Yes. No, not at this time, we've not. We've not seen any significant changes in that -- in those habits at all.

Your next question comes from the line of Joanne Wuensch with Citi.

This is Matt Henriksson in for Joanne. First question we had is just around Mako and robotic knee systems. You guys had a great quarter, great momentum ending the year. But J&J's coming out with their VELYS robot. They received FDA approval. And also Zimmer's kind of in full swing with their launch. So just kind of putting the 2 together, is there any change in your commercial plans as you now have more technology out in the market?

Yes. Sure. This is Kevin. I'll take that. First thing I would tell you is the introduction of competitive systems has not slowed down or make a momentum whatsoever, and we don't expect that to change with one more system on the market. If anything, it just proves to further validate that robotics is here to stay in orthopedics. And we really believe we have the best solution on the market, as evidenced by the uptake in the procedures. And we disclosed the fourth quarter, almost 1 out of 2 is in United States being used with Mako. So surgeons absolutely love our system, and they're using it at very, very high rates.

There also is a synergy with the way that our system ensures an absolutely perfect cut and with haptics, which we're the only ones that have. That is very complementary with cementless. And you see both of those adoption rates moving in the same direction. So we love our chances of competing side-by-side with anybody, and we think this provides a further tailwind in the adoption of robotics in orthopedics.

Some good color. And then for a follow-up, just going to the Wright Medical acquisition. Before they were acquired, they had always talked about their enabling technology. Their preoperative planning software being kind of their main driver to capture share and to expand the market. Has that strategy changed at all now that you are beginning to integrate with them? Or are you going to continue kind of with that strategy of focusing with enabling technology first?

Yes. What I would tell you is that certainly, we've always been believers of enabling technologies, as evidenced by some of the different businesses that we've acquired and some of the different products that we've launched and really with a focus on improving patient outcomes. And we believe that a lot of those technologies, including the BLUEPRINT technology that Wright had previously invested in, are complementary really to some of the platforms that we have.

And as part of the integration with the Wright organization, the R&D portfolio and technology teams, they're all working together really to build out what those long-term pipeline plans are going to be and really leveraging all of the different unique products and capabilities from both sides. So we will continue to see investments in those areas.

Your next question comes from the line of Kaila Krum with Truist.

So I appreciate the guidance that you gave for 2021. Can you just speak to how you think each segment of the business will grow relative to the total organic range you provided? And I guess I'm most curious, just looking at MedSurg and Orthopaedics, you're assuming some of Medical, the demand slows down in the coming quarters and that backlog kicks up in ortho? Just any more detail on that would be super helpful.

Yes. So Kaila, we don't typically provide any of that segment breakdown in terms of our guide. But I think if you just take a look at what we're expecting to happen in the marketplace and what's really been happening through 2020 and as we go into 2021, certainly, those businesses that we have that are affected are more affected by elective procedures should see the benefit of elective procedures returning throughout the year.

The other thing I would just say, as Kevin had mentioned, too, are smaller capital products, really, those products that are facilitating many of those elective procedures should also see some of that benefit.

And then as it pertains to really the large capital segment, we've continued to see strong demand in those areas and would expect to continue to see some of that demand throughout '21 as well.

Okay. And then just to follow-up, I guess, to Pito's question earlier. Is it fair to say that I mean Q1 will be sort of the softest of the year? Q2 will have the highest growth, kind of off an easier comp and the second part of this year should feel a little bit more normal?

I think it's certainly fair to say that the variability that we experienced in the fourth quarter, we expect that to continue into the first quarter. And then we should see benefits happening as we progress throughout the remainder of the year.

Your next question comes from the line of Steven Lichtman with Oppenheimer.

First, I was wondering if you could provide some additional color around the ASC sales model that you're rolling out. Any details you could provide on what the model looks like and the early feedback from the field would be great.

Yes. So I'm not going to get into too much detail, just for competitive reasons, but I would say that I'm delighted with the ASC offense that we put in place. It involves people from different parts of Stryker that basically quarterback the deal and bring in multiple divisions based on the unique needs of every ASC.

Every ASC is unique. Every deal is a customized deal. But the way we've navigated this enables incredible collaboration across our divisions. We've put just absolutely fantastic people in charge. And really, we have the breadth of our portfolio with capital, equipment, disposables and implants. And really, for the first time as a company, we're really leveraging that in the United States. We have had success with such models, sometimes in other countries around the world, but in the U.S., this ASC model has been truly fantastic, exceeded my expectations. And I'm bullish that they'll be able to continue to have great success in the ASCs.

And frankly, Mako is often part of that formula in the ASC. Not always. We obviously had a presence before with sports, but that business, fortunately, has really started to grow. As you even heard in the fourth quarter, in spite of the pandemic, it grew over 9%. And so having a strong sports business plus all of our other businesses and now with Wright having Extremities, category-leading position, we just have a fantastic portfolio to serve the needs of the ASC, and now a commercial offense, again, not getting too specific, but let's just say, we make it easy for the ASC, and we provide customized solutions.

Got it. And then just a follow-up on the fourth quarter. How did your Spine franchise specifically hold up during the recent spike in COVID cases? And any thoughts on that business overall looking into 2021?

Yes. I would say that the Spine business held up a little bit better. We saw spine procedures, in general, holding up a little better than some of the other elective procedures, particularly for our Spine business outside the United States performed well. And I think it's just a function of the successful integration that we've had with the K2M business and combining that with some of the enabling technologies like those that we acquired through Mobius. And again, we saw some continued performance in some of the markets outside the U.S. that had more stability in spine-related procedures like Japan and Canada as well.

So I think all in all, it held up a little bit better. We definitely expect that business to continue to perform well as we go into 2021 and really harnessing the power across K2M, our legacy Spine business as well as the enabling technologies.

Your next question comes from the line of Matt Taylor with UBS.

So I thought the disclosures on Mako were really interesting and bullish, and just had 2 follow-ups on that. One is, where do you think you can push Mako penetration and cementless penetration in the U.S. over time? And would love to hear your thoughts OUS, both on that question and just on the opportunity given you just had all these approvals in new geographies.

Yes. Thanks. So certainly, I'm delighted with the progress, both with Mako adoption as well as cementless. I don't think cementless will ever get to where it is with hips just because of bone stability. It's a weight-bearing joint. But clearly, we now see it's going to be significantly higher than 50%, which I think 5 years ago, nobody would have believed if we had said that. So that's pretty remarkable.

In terms of the actual use of Mako. As you saw, we had a lot of robots installed this year. So I would expect that looking at the percentage of knees done with Mako will continue to increase, same with hips.

Outside the United States, it's taking a little longer, obviously, because of the approvals. But we're really excited about getting the total knee approved in China, Brazil and Russia. And certainly, Japan and China are going to be very, very good markets for us. Japan, we've made some progress already. The approvals took a little longer there as well. But the new hip software, of course, is also very important. As you know, there's a lot more hip procedures done in that part of the world. It's almost about the same as knees, unlike the United States.

So we love the fact that we have multiple applications all approved in those markets and would expect you're going to see a similar kind of growth that you saw in the United States. It may not be quite as quick, and you've seen that, frankly, with Intuit in soft tissue robotics. The uptake is a little slower outside the United States. But we expect the same kind of runway longer term and are very bullish about the prospects, especially in China, Japan, Brazil, for sure, are going to be terrific markets for Mako.

Okay. Great, great. Maybe just a quick follow-up on that. Right in the house now, could you give us updated thoughts on the timing on a robotic solution for shoulders and for spine?

We're not really ready to give time line yet. We have to get a lot closer to launch before we're going to be specific about time lines. I would say that I'm extremely bullish about shoulder. I think I've said that in the past. It's a very difficult procedure to do. There are enabling technologies within Wright that we're -- our teams are working on with our Mako teams. And we'd be very excited to be able to bring that to the market with their market-leading implants. But not yet ready for time lines. And same with Spine, not yet ready for time lines. We have 2 options for Spine. One is the robotic program that was being developed by Mobius prior to the acquisition as well as Mako. We have work going on in both areas but just not ready to give time lines. Robotics is complicated, and we will keep you posted.

Your next question comes from the line of Ryan Zimmerman with BTIG.

Just first for me, Kevin, around the capital equipment demand. I was just wondering if you could talk about kind of the dynamics in play in 2021. You've been very strong with beds, and you haven't said much about maybe booms and lights. And so is this a story of kind of the first half, second half? And how to think about that composition of capital equipment moving from the first half to the second half and what that may entail in terms of your portfolio?

Yes. So booms and lights certainly haven't been as positive as Mako and the beds and stretchers and certainly, the defibrillators because the Medical capital really did sort of have to ride a bit of a pandemic tailwind, if you will. And booms and lights large construction sort of slowed down a little bit. That should pick up starting next year. And that's part of the drag that you see within the Endoscopy division is the booms and lights portion. But certainly, in ASCs, they're busy, but certainly the large capital spend projects were delayed a little bit. They're starting to pick back up again. So that's obviously a smaller business, but then the overall Stryker.

But Medical, we continue to feel bullish. So it's -- so we did get a bit of pandemic benefit. But this new bed that we've launched is really a fantastic product, getting great customer feedback. Sage has also picked up. So that was really hit hard in the second quarter, third quarter. Had a nice pickup in Q4. And that business will resume its high growth as the pandemic subsides.

So the diversity of our portfolio is really -- that gives us the optimism that we're going to continue to see strong growth in Medical. And it wasn't just sort of a pandemic bump and then will suddenly drop because of the innovation in our portfolio and, frankly, just really, really strong commercial execution.

Okay. Understood. And then just a follow-up from me. Another business that doesn't get a lot of attention is sustainability. And I'm just wondering if there's been any change in practice due to COVID and demand for that business and kind of the whole reprocessing market itself with hospitals and how to think about that over time as we potentially normalize and the strength of what that can or can't do. Again, I appreciate that it's small.

Yes. Sure. No, I would just say that it's -- those products are used in discretionary or elective procedures. So they were directly hit in the same way that you saw our other deferrable procedures being hit. And so because of the nature of those products, as the pandemic subsides, that growth will pick up. So there's nothing more to read into it than that. Our hospital behaviors are -- didn't really change either positively or negatively. It's if you can do the procedures, they'd use the products. If those procedures were sort of shut down, then those products weren't being used and then they weren't being purchased. So I would expect it to follow a similar pattern just based on other elective procedures.

Your next question comes from the line of Matt O'Brien with Piper Sandler.

This is Drew on for Matt. I just wanted to start off briefly on Wright. Maybe you guys could help us by comparing and contrasting the Wright integration process to the one you went through with K2. What stage of the process have you already completed so far considering the longer deal close time line? And then I guess, really, what I'm trying to get at is about a year into the K2 process, you ran into a couple of additional challenges. Do you feel you have a good head start with that for Wright? And what gives you confidence in the contribution you baked into guidance?

Yes. So certainly, as I think about those 2 acquisitions, there are some similarities, and then there are some pretty big differences. The similarities maybe lie in the foot and ankle side, where there is more of a true integration what's happening between the Stryker business and the Wright business. But for the upper extremities side, it's much more of just bringing them into Stryker and continuing on with the growth that they've had.

So it's a little bit different from that perspective as we think about bringing on the acquisition of Wright versus K2. Just like with any -- in all of our previous acquisitions, we've learned and we've learned along the way and we use those learnings as we plan for additional or new acquisitions that are coming. The same was true with Wright. And so we utilized really that year-long period between sign and close to ensure that we're focused on getting the correct integration plans in place so that we can hit the ground running. And to date, that's what the team has done. They have executed to the plan. And as I'd mentioned in my prepared remarks, we've really done a lot of focus on ensuring that the sales organizations are being integrated in a timely fashion. And so that's where we are at this point. And certainly, we'll continue to provide some updates as we continue with the integration throughout the year.

Okay. That's super helpful. And then I appreciate the commentary on Mako and ASCs. It sounds like your placement mix continued to shift a little bit today I see here in Q4. So I guess the question is, as we look out a year in a post-COVID environment, do you see the interest from ASCs tapering down any? Or do you think it continues ramping over the long term?

Yes. I think the trend to the ASC is -- it was already accelerating prior to the pandemic. It's going to continue, without a doubt, especially for hip and knee procedures, foot and ankle procedures, even some basic spine procedures. So I think this is a permanent trend. It will continue. And obviously, now we have reimbursement coverage for hips as well as knees through Medicare. So I think this is a trend for the future.

And I actually think it's not going to stop in United States. There's already countries like the U.K. and even Canada looking at moving to lower cost sites of care. It's a good thing for health care overall. And these surgery centers make good money. They're very profitable. They don't have the burden of the cost of large inpatient hospitals. So you can debate the actual pace of the curve, but there's no doubt in my mind that this is a trend that's going to continue to accelerate.

Your next question comes from the line of Richard Newitter with SVB Leerink.

A couple of quick ones on Orthosensor and then a follow-up on Orthosensor. Can you just remind us what you plan on doing with the intraoperative, the VERASENSE capability? I know that some of your competitors currently use that system. Are you going to continue to sell that as an open architecture? And then second on Orthosensor is just should we think of when you do offer your first iteration of a product there, whether it's a wearable, external or whatever it looks like? Is that going to be something that you'll charge separately for? Or do you think you'll package it in with the procedure?

Yes. Thanks for the question. So on OrthoSensor, obviously, it's new under the belt here a few weeks. And so it's not something that we have fully developed all of the various plans in terms of how we're going to market for any of the products at this point in time. And so as that happens, we'll certainly be able to come back and give you updates with regards to how we're going to market and what the impacts might be in terms of what the legacy business was and what we expect it to be in the future.

And I think the same holds true as we think about the future product launches as well. As I mentioned before, we haven't defined all of those time lines yet. And so all of the items that you bring out in terms of how it will commercialize, how it will be sold, et cetera, will all be developed and done at that point.

And if I could just one more. On the M&A front, congrats on getting Wright Medical finally over the finish line there. I guess, should we think of you as very much out in the market? Size of deals, everything's fair game and back to kind of normal Stryker M&A, not just small tuck-ins? Or maybe anything you would care to comment on or share with respect to your view of the M&A outlook?

Sure. I think, obviously, we took on additional debt when we did the Wright Medical acquisition. We've also made commitments to reduce our debt over the next few years. And so that will be something that's ongoing. And you'll see that in our financial performance.

But because M&A is so important to our growth strategy -- and keep in mind that our normal M&A strategy is really just smaller tuck-in deals. It's what we do well. It's what we do best, and we can execute those quickly. So I think just like with Orthosensor, you'll see us continuing with smaller tuck-in acquisitions like we normally do through the year. And I don't anticipate that you'll see a sort of a big acquisition of the size of Wright Medical for a couple of years.

And frankly, if you think back to even when we did Sage and when we did Physio, those were 2 very large acquisitions. We moved into a strategy for a year or 2 of just doing tuck-ins, which served us very well. And so I think it will play out very similar to that.

Your next question comes from the line of Mike Matson with Needham & Company.

I guess I wanted to ask about the ProCuity bed launch. Maybe you can give us an update on where things stand with that. And I was wondering if you could give us an overview of the kind of smart bed capabilities that you're planning for that platform?

Sure. So that is out in the market in a limited way in the fourth quarter, really rolling out for a full launch as we think about the first quarter of 2021.

In terms of the features and benefits, really, it's 3 things I would probably point out to. I think, one, just advanced fall prevention, really focusing on keeping patients safe as well as we think about low height feature. I think the bed drops down to about 11 inches off the floor. And then also, it's the first bed that's really truly wireless. And so really, all of those items trying to meet some unmet needs in the marketplace to drive benefits into that market.

Okay. And then I know you're not giving specific guidance for the margins for 2021. But just given there's several moving parts, particularly gross margin, you've got Wright, which I think is coming in at a higher gross margin, but then you had some fixed cost absorption issues in 2020 that could spill into 2021. Can you give us any kind of insight into where you expect the gross margin to end up and kind of the sequence of that throughout the year?

Yes. Actually, I think you did a pretty good job summarizing it. Wright will definitely come in and be accretive to our gross margin as those products generally have a higher gross margin than sort of the average of our other business.

I also think, too, as you look at business mix, that will normalize as the year goes forward. And so we'll also see kind of those higher-margin Orthopaedics products becoming a bigger share of the total. And I think we'll largely come back to sort of what our view is sort of normalized margins as you look at 2019.

Conversely, though, just as a reminder, moving down to op margin, you are going to see that discretionary spending tick up as we support growth. And so that will likely go the other way. And we'll be on a ramp, largely a sales ramp, throughout the year.

Your next question comes from the line of Josh Jennings with Cowen.

This is Eric on for Josh. Looking at the 4Q performance on Hip for a minute, this is a procedure category that we have been thinking perhaps would be a little more resilient through any pandemic headwinds in the quarter. I was just wondering if you could share your thoughts on that business, particularly in the U.S., excuse me, and just help us understand what's behind that result.

Yes. So I think Kevin outlined it pretty well before. I mean, I think overall, just looking at 1 quarter in the midst of a pandemic is tough to do because of the variability and really the localized impacts that we were seeing from an elective procedure standpoint.

So certainly, you would expect that hips might be a little less deferrable than knees, just given the nature of the disease and degeneration. But at the same time, elective procedures, depending on where you were in the world, were being stopped. And so hips were not immune to that, like some of our other elective procedures.

As we look forward, certainly, with the rollout of all of the installations for Mako that we've done this year as well as our new hips software, we're really expecting continued above-market growth from our hips and knees as we move forward.

Understood. And then quickly, I was wondering if you were able to share what percent of the Wright business is levered to outpatient procedures.

No. That's not something that we're sharing.

Your next question comes from the line of Jeff Johnson with Baird.

Most of my questions have been answered, but I guess, just one last one. Just it sounds like China and Latin America held in better in the fourth quarter. Have you seen any change in that trend line over the last few weeks or as we've gone into 1Q here? Just are those continuing to hold in better than some of the European and U.S. markets? Or anything we should be thinking about even in those markets early in the year?

Yes. I would tell you, we haven't seen any significant trend shift heading -- making that transition from fourth quarter in the first quarter.

Your next question comes from the line of Kyle Rose with Canaccord.

I just had 2 questions. One, Kevin, you mentioned sports being a pocket of strength. Just wondering if you could flesh that out for us. Really what's driving that is the new product set that we should be focused on? And then secondarily, you talked a lot about building a connected ecosystem of implants and enabling technologies. I think we understand the opportunity with Mako pretty well. We've clearly got Orthosensor that's going to flow in, but maybe just help us understand what that means for the company longer term. Does it bring you close to your customers and prevent share loss or competitive loss? Are there new revenue streams that come in, just from a big picture perspective, how should we be thinking about that over the next several years?

Okay. Sure. So I'll start with the second part. The world is obviously going more and more digital. We have a Stryker health cloud. There's all types of data that we're collecting from Mako that we want to be able to mine that data with thousands and thousands of procedures already being done and really connect that with sensors. So we really see this as not just limited to general replacement. It's going to be across all of our businesses, whether it's trauma, whether it's craniomaxillofacial, sports. And so this is something we're really excited about. And we named Robert Cohen the head of that business on behalf of all of Stryker.

And so we already had initiatives going on in different parts of the company. We're sort of bringing it all together to really create more leverage and really be able to have Centers of Excellence around different types of technology blocks.

And so to us, it's extremely exciting. Robert knows the company very, very well. As I think many of you know, Robert, very well positioned to lead this function for the company. And sorry, can you repeat the first question again? I'm sorry about that. I didn't catch that.

Yes. I mean just about the strength that you saw in the Sports Medicine side of the business?

Oh, sports. Yes. So sports has been just a fabulous story for Stryker that when I joined the company almost 10 years ago, our Sports Medicine implant business was really tiny. Most people didn't even know we had a Sports Medicine implant business. And we have grown it pretty dramatically since then, primarily through internal innovation, but we've also done a series of very small acquisitions. One of them was Pivot, you may recall, for hip arthroscopy.

More recently, we launched a lateral row anchor for shoulder, which has been, we call it, Omega, the product name, which is a fantastic product. We picked up -- through [IVR], we picked up another product as well, which -- these are all key fundamental products, whether it's in knee, whether it's in hip or whether it's in shoulder. So now we have all 3 of the joints very well covered in sports. And we are just growing at a very, very robust rate. And the timing couldn't be better with the shift to the surgery center and being able to use sports combined with our other divisions.

Again, we really ported on in the last few years in sports with a lot of investment internally that we've done. And we have a fabulous leader. That business is run out of Denver. And we're really excited about the progress we've made in sports.

Your next question comes from the line of Matt Miksic with Crédit Suisse.

So just one on shoulder and Wright and one on -- just a follow-up on some of your comments on market share trends. So wondering if you could talk a little bit about your thoughts on the overlap of Wright surgeon customers in shoulder with sort of your traditional end markets? And what, if any, opportunity there is there for sort of cross-selling or going through relationships, that sort of thing? And then as I mentioned, just one quick follow-up.

Yes. Sure. So clearly, Wright Medical had a much bigger shoulder business than Stryker. And a lot of the Stryker business, frankly, were you the hip and knee surgeons that also did some volume of shoulder. And the teams are obviously working on that through the sales deployment, figuring out which surgeons are going to be allocated to which salespeople. They made great progress on that front.

And cross-selling opportunities will exist. But as Preston mentioned before, this integration is not going to be as tricky as the integration on foot and ankle, just given that we tended to -- they tended to be strong with the, I'll call it, fully dedicated upper extremity surgeons. And we tended to be stronger with those surgeons that did a smaller number, just as a general statement. So I think this integration is going to be terrific.

We were really thrilled to be able to have the leader from Wright Medical take over the combined business of upper extremities. And their Head of Sales is also running the combined sales organization, and they're both outstanding leaders. And we are delighted not only to bring the business and the products of Wright Medical but being able to bring over some of their key leadership. Even the leader of our combined foot and ankle business came from Wright Medical. So not only are we bringing over great technologies, we're also bringing over great talent with that acquisition.

That's great. And then just to follow-up on sort of market trends. I think you mentioned here just in Q&A that you expect to continue to grow above the market in joints or in orthopedics or in knees, if I heard correctly. I'm just wondering, for clarity, looking back on Q4, understanding a lot going on in regional differences, et cetera. But is it your -- is your expectation that your numbers there also represent sort of above end market procedure growth? Or is it just too hard to talk about that given the variability?

Matt, I would just tell you, at this point, it's very difficult to really talk about it, just given the variability. I mean it's not dissimilar to what we've seen really in second and third quarter as well in terms of how the surgeries are being deferred and where they're being deferred and how they're coming back. So I think that really is difficult to use 1 quarter, certainly difficult in the midst of this pandemic to use 1 quarter. So I think as we look at it, we're looking at -- as we get to those normalized rates and knowing what we've done from a Mako implement -- a Mako placement and install standpoint that we have a lot of runway to go in terms of growing our Hips and Knees.

There are no further questions at this time. I will now turn the conference over to Mr. Kevin Lobo for any closing remarks.

So thank you all for joining our call. Thank you. I'm very, very pleased to have 2020 behind us and looking forward to a strong year in 2021. We have to get through, obviously, the remainder of this pandemic. But as you saw from our guide, we are feeling very confident about the future. And we look forward to sharing our Q1 results with you in April. Thank you.

Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.